Ardelyx, Inc. (ARDX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.99-9.12%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ARDX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||
| Revenues | 468.2 | 407.3 | 333.6 | 124.5 | 52.2 | 10.1 | 7.6 | 5.3 | 2.6 | 42.0 | 24.0 | 24.0 | 31.6 |
| Total Revenues | — | — | — | — | — | — | — | — | 2.6 | 42.0 | 24.0 | 24.0 | 31.6 |
| Cost of Revenues | 26.0 | 39.5 | 50.6 | 17.8 | 4.1 | 1.0 | 0.1 | 0.6 | 0.5 | 8.4 | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | 4.7 | 2.1 | 33.6 | — | — | — |
| Operating Expenses & Income | |||||||||||||
| Selling, General & Admin | 384.0 | 337.2 | 258.7 | 134.4 | 76.6 | 72.3 | — | — | — | — | — | — | — |
| R&D Expenses | 94.3 | 71.5 | 52.3 | 35.5 | 35.2 | 91.1 | 65.1 | 71.7 | 69.4 | 75.5 | 94.2 | 39.9 | 25.9 |
| Operating Income | (36.1) | (41.0) | (28.0) | (63.3) | (63.8) | (154.3) | (90.8) | (91.3) | (90.9) | (65.1) | (112.9) | (29.4) | (1.6) |
| Earnings from Continuing Operations | |||||||||||||
| Interest Expense | — | 20.1 | 13.0 | 5.0 | 3.4 | 4.5 | 5.1 | 5.7 | 3.5 | — | — | — | — |
| Other Non-Operating Income / Expenses | 8.9 | 8.7 | 9.2 | 6.6 | 1.6 | 0.7 | 1.6 | 2.4 | 3.2 | 2.0 | 0.5 | — | — |
| EBT, Incl. Unusual Items | (55.3) | (60.6) | (38.9) | (65.5) | (67.2) | (158.2) | (94.3) | (94.6) | (91.3) | (63.2) | (112.4) | (29.7) | (3.1) |
| Income Tax Expense | 0.2 | 1.0 | 0.3 | 0.5 | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 | 1.2 | (0.0) | (0.0) | 0.1 |
| Net Income | |||||||||||||
| Net Income | (55.9) | (61.6) | (39.1) | (66.0) | (67.0) | (158.0) | (94.3) | (94.9) | (91.3) | (64.3) | (112.4) | (29.6) | (3.2) |
| Per Share | |||||||||||||
| Basic EPS | (0.22) | (0.26) | (0.17) | (0.30) | (0.42) | (1.52) | (1.05) | — | — | — | — | — | — |
| Diluted EPS | (0.22) | (0.26) | (0.17) | (0.30) | (0.42) | (1.52) | (1.05) | — | — | — | — | — | — |
| Revenue per Share | 1.87 | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 250.0 | 241.0 | 235.2 | 219.3 | 158.7 | 104.2 | 89.6 | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 250.0 | 241.0 | 235.2 | 219.3 | 158.7 | 104.2 | 89.6 | — | — | — | — | — | — |
| Supplemental | |||||||||||||
| EBITDA | — | (37.9) | (25.9) | (62.0) | (62.6) | (151.5) | (89.0) | (88.8) | (88.2) | (62.5) | (111.6) | (28.6) | (1.3) |
| EBIT | (36.1) | (41.0) | (28.0) | (63.3) | (63.8) | (154.3) | (90.8) | (91.3) | (90.9) | (65.1) | (112.9) | (29.4) | (1.6) |
| Effective Tax Rate | -0.4% | — | — | -0.8% | -0.0% | -0.0% | -0.0% | -0.3% | -0.0% | -1.9% | 0.0% | 0.1% | -2.1% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.